🏢 官网IRVIRCodex · 实盘不做把握 9/10
北京时间·🕒 发布 04:05:00时区推断·⟳ 抓取 04:09:03·⚡ 决策 07-23 04:10:56 +1m53s·96.9 天前
Vir Biotechnology宣布将召开2026年二季度业绩电话会
公司仅公告将于2026年8月5日召开二季度业绩电话会并提供公司更新，没有披露业绩数据、指引变化、临床进展或交易性增量信息。
📄 原文VIR↗ 原文
Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results
--> (opens corporate site in new window) --> Powering the Immune System to Transform Lives --> News Details View all ne…
不做 Vir Biotechnology（VIR.US）
仅为二季度业绩电话会排期公告，没有业绩超预期、指引上修、临床进展或其它可交易新增事实，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-22 · 扩散 low · price-in 风险 medium ↗
关键理由
- 公司仅公告将于2026年8月5日召开二季度业绩电话会并提供公司更新，没有披露业绩数据、指引变化、临床进展或交易性增量信息。
主要风险
- 若后续电话会实际披露超预期临床或财务信息，应由新信号重新研判。
原文全文
展开原文 · 1,709 字
-->
(opens corporate site in new window)
-->
Powering the Immune System to Transform Lives -->
News Details
View all news
Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results
07/22/2026
Download (opens in new window) PDF 180 KB
SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, August 5 to provide a corporate update and discuss its financial results for the second quarter ended June 30, 2026. The conference call may be accessed on the Events & Presentations page of the Vir Biotechnology website.
About Vir Biotechnology
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN ® dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.
Vir Biotechnology retains exclusive rights to the PRO-XTEN ® masking platform for oncology and infectious disease. PRO-XTEN ® is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.
Media Contact
Caren Scannell
Director, Communications
cscannell@vir.bio
Investor Contact
Kiki Patel, PharmD
Head of Investor Relations
kpatel@vir.bio
Source: Vir Biotechnology, Inc.
Multimedia Files:
View all news
(opens corporate site in new window)
-->
Powering the Immune System to Transform Lives -->
News Details
View all news
Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results
07/22/2026
Download (opens in new window) PDF 180 KB
SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, August 5 to provide a corporate update and discuss its financial results for the second quarter ended June 30, 2026. The conference call may be accessed on the Events & Presentations page of the Vir Biotechnology website.
About Vir Biotechnology
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN ® dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.
Vir Biotechnology retains exclusive rights to the PRO-XTEN ® masking platform for oncology and infectious disease. PRO-XTEN ® is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.
Media Contact
Caren Scannell
Director, Communications
cscannell@vir.bio
Investor Contact
Kiki Patel, PharmD
Head of Investor Relations
kpatel@vir.bio
Source: Vir Biotechnology, Inc.
Multimedia Files:
View all news
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。